Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2013 | short review

Aggressive lymphoma at ASH 2012: new standards and new perspectives

verfasst von: Thomas Nösslinger, Thomas Nösslinger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. R-CHOP remains the standard for first line treatment in diffuse large B-cell lymphoma, though, several new therapeutic agents such as lenalidomide and ibrutinib are now tested in clinical trials as single agent or in combination with established therapies. Finally, some new therapeutic options for the unfavorable subset of T-cell lymphoma were presented.
Vorheriger Artikel ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update
Nächster Artikel ASH 2012: allogeneic stem cell transplantation
Literatur
1.
Hermine O, Hoste E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net). Blood. 2012;118 (abstr 151, ASH Annual Meeting Abstracts).
2.
Flinn I, Van der Jagt R, Kahl B, et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or Mantle cell lymphoma (MCL): the bright study. Blood. 2012;118 (abstr 902, ASH Annual Meeting Abstracts).
3.
Kahl B, Li H, Smith MR, et al. Mature results from ECOG study E1405—a phase II study of VcR-CVAD with maintenance rituximab for previously untreated mantle cell lymphoma. Blood. 2012;118 (abstr 153, ASH Annual Meeting Abstracts).
4.
Goy A, Sinha R, Williams ME, et al. Phase II multicenter study of single-agent lenalidomide in subjects with mantle cell lymphoma who relapsed or progressed after or were refractory to bortezomib: the MCL-001 “EMERGE” study. Blood. 2012;118 (abstr 905, ASH Annual Meeting Abstracts).
5.
Wang M, Rule S, Martin P, et al. Interim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood. 2012;118 (abstr 904, ASH Annual Meeting Abstracts).
6.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with Chop alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–42.PubMedCrossRef
7.
Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma. A randomized controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol. 2006 May;7(5):379–91.PubMedCrossRef
8.
Fridrik M, Petzer A, Keil F, et al. Non-pegylated liposomal encapsulated doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma. Final results of a randomized trial. Blood. 2011;117 (abstr 2676, ASH Annual Meeting Abstracts).
9.
Récher C, Coiffier B, Hajoun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open label randomized phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858–67.PubMedCrossRef
10.
Fridirik M, Hausmaninger H, Linkesch W, et al. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. J Clin Oncol. 1996 Jan;14(1):227–32.
11.
Nowakowski G, LaPlant B, Reeder C, et al. Combination of lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-cell lymphomas—a phase II study. Blood. 2012;118 (abstr 689, ASH Annual Meeting Abstracts).
12.
Chiappella A, Franceschetti S, Castellino A, et al. Rituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): results of phase II REAL07 study of the Fondazione Italiana Linfomi (FIL). Blood. 2012;118 (abstr 903, ASH Annual Meeting Abstracts).
13.
Seymour J, Pfreundshuh M, Coiffier B, et al. The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study. Blood. 2012;118 (abstr 58, ASH Annual Meeting Abstracts).
14.
Wilson W, Gerecitano J, Goy A, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood. 2012;118 (abstr 686, ASH Annual Meeting Abstracts).
15.
Swinnen L, Li H, Quon A, et al. Response-adapted therapy for diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) based on early [18F] FDG-PET scanning: an eastern cooperative oncology group study (E3404). Blood. 2012;118 (abstr 687, ASH Annual Meeting Abstracts).
16.
Fanale M, Shustov A, Forero-Torres A, et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. Blood. 2012;118 (abstr 60, ASH Annual Meeting Abstracts).
17.
d’Amore F, Leppä S, Gomes da Silva M, et al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without Alemtuzumab and consolidated by high dose therapy. Blood. 2012;118 (abstr 57, ASH Annual Meeting Abstracts).
Metadaten
Titel
Aggressive lymphoma at ASH 2012: new standards and new perspectives
verfasst von
Thomas Nösslinger
Thomas Nösslinger, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0086-8

Weitere Artikel der Ausgabe 3/2013

Focus on gastrointestinal tumors

  • Editorial

Radiofrequency ablation in gastrointestinal cancer: obstacles and goals

  • short review

ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update

  • short review

Upper gastrointestinal cancer: POST ASCO 2013

  • short review

Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

  • short review

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

  • short review